Table 3.

Application of ⁸⁹Zr-mAb in clinical oncology studies

Year	mAb	Target	Tumor type	Refs.
2006	Chimeric mAb U36	CD44v6	Head and neck cancer	[37]
2012	Ibritumomab-tiuxetan	CD20	B cell lymphoma	[38]
2013	Bevacizumab	VEGF-A	Breast cancer	[39]
2014	Bevacizumab	VEGF-A	Neuroendocrine tumors	[40]
2015	Fresolimumab	TGF-β	Glioma	[41]
2016	MMOT0530A	MSLN	Pancreatic, ovarian cancer	[42]
2017	Cetuximab	EGFR	Head and neck, lung cancer	[43]
2017	Rituximab	CD20	B cell lymphoma	[44]
2017	Lumretuzumab	HER3	Multiple cancer types	[45]
2017	Bevacizumab	VEGF-A	Metastatic renal cell carcinoma	[46]
2018	Trastuzumab	HER2	Breast cancer	[47]
2018	Atezolizumab	PD-L1	Bladder cancer, non-small cell lung cancer, triple-negative breast cancer	[48]